The U.S. Food and Drug Administration (FDA) has announced that it will significantly restrict the use of the diabetes drug rosiglitazone (brand name, Avandia) to patients with Type 2 diabetes who cannot control their diabetes on other medications. Their decision is in response to data that suggest an increased risk of cardiovascular events, such as heart attack and stroke, in patients who were treated with rosiglitazone...
Read from Source
|
